A very early clinical response to treatment with the Janus kinase inhibitor tofacitinib in patients with active rheumatoid arthritis: the dynamics of pain and central sensitization elements
Authors:
- 30 May 2020
- journal article
- research article
- Published by IMA Press, LLC in Modern Rheumatology Journal
- Vol. 14 (2)
Abstract
Janus kinase (JK) inhibitors block the intracellular signaling pathways that are responsible for the synthesis of proinflammatory cytokines and mediators, which in turn cause the activation of pain receptors and central sensitization (CS). It is suggested that JK inhibitors can rapidly eliminate pain and reduce the severity of CS.Objective: to evaluate the effect of the JK inhibitor tofacitinib (TOFA) on the intensity of pain and the signs of CS in patients with active rheumatoid arthritis (RA) at 7 and 28 days after therapy initiation.Patients and methods. A study group consisted of 39 patients (79.5% female) (mean age 50.9±11.1 years) with RA (DAS28 5.8±0.6). Of these, 89.7% were seropositive for rheumatoid factor; 82.0% took methotrexate and 18.0% received leflunomide. All the patients were prescribed TOFA 5 mg twice daily due to the inefficacy or intolerance of biological agents. The investigators estimated pain intensity using a Brief Pain Inventory (BPI), rated the presence of a neuropathic pain component (NPC) with the PainDETECT questionnaire, and assessed the signs of CS with the Central Sensitization Inventory (CSI) during the first 4 weeks after TOFA administration.Results and discussion. The patients initially experienced moderate or severe pain (the mean scores of 5.33±2.51 on the numerical rating scale (NRS) included in BPI); 53.8% had signs of CS (CSI scores of ≥40); 17.9% had signs of a NPC (PainDETECT scores of >18). Already on day 7 after the start of TOFA administration, there was a statistically significant decrease in the mean NRS pain intensity scores to 4.06±2.2 (p=0.01) and by 29.4±17.9%, as shown by the patient's assessment of the analgesic effect of therapy (BPI), as well as the severity of CS, namely a decrease in the mean NRS pain score to 35.9±11.2 (p=0.01). On 28 days, the effect became better: there was a reduction in the level of NRS pain to 2.32±1.57 (pConclusion. The use of the JK inhibitor TOFA can achieve a rapid analgesic effect, inter alia due to its effect on CS and NPC.Keywords
This publication has 14 references indexed in Scilit:
- Rheumatoid arthritis: achievements and unresolved issuesTerapevticheskii arkhiv, 2019
- Inhibition of pSTAT1 by tofacitinib accounts for the early improvement of experimental chronic synovitisJournal of Inflammation, 2019
- JAK/STAT Blockade Alters Synovial Bioenergetics, Mitochondrial Function, and Proinflammatory Mediators in Rheumatoid ArthritisArthritis & Rheumatology, 2018
- Cross-cultural adaptation and validity of the Italian version of the Central Sensitization InventoryMusculoskeletal Science and Practice, 2018
- The role of the JAK/STAT signal pathway in rheumatoid arthritisTherapeutic Advances in Musculoskeletal Disease, 2018
- Chronic Pain in Inflammatory Arthritis: Mechanisms, Metrology, and Emerging Targets—A Focus on the JAK-STAT PathwayPain Research and Management, 2018
- Tofacitinib in Psoriatic ArthritisImmunotherapy, 2017
- Establishing Clinically Relevant Severity Levels for the Central Sensitization InventoryPain Practice, 2016
- The IL-6/gp130/STAT3 signaling axis: recent advances towards specific inhibitionCurrent Opinion in Immunology, 2015
- NEW APPROACHES TO PHARMACOTHERAPY OF RHEUMATOID ARTHRITIS: TOFACITINIBRheumatology Science and Practice, 2014